Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALN-BCAT |
| Synonyms | |
| Therapy Description |
ALN-BCAT comprises siRNA targeted against beta-catenin (CTNNB1) in a lipid nanoparticle formulation, which potentially increases antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 5924). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALN-BCAT | ALNBCAT|ALNBCAT | ALN-BCAT comprises siRNA targeted against beta-catenin (CTNNB1) in a lipid nanoparticle formulation, which potentially increases antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 5924). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06600321 | Phase I | ALN-BCAT + Pembrolizumab ALN-BCAT | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Recruiting | USA | ITA | 1 |